ADVANCED MESENCHYMAL STEM CELL DEVELOPMENT
Solicitation number W7702-155729/A
Publication date
Closing date and time 2015/05/25 16:00 EDT
Last amendment date
Description
Trade Agreement: Agreement on Internal Trade (AIT) Tendering Procedures: The bidder must supply Canadian goods and/or services Attachment: None Competitive Procurement Strategy: Best Overall Proposal Comprehensive Land Claim Agreement: No Nature of Requirements: 1. TITLE: ADVANCED MESENCHYMAL STEM CELL DEVELOPMENT 2. SECURITY REQUIREMENTS: 2.1 The following security requirements apply and form part of the Contract. Security Requirement for Canadian Supplier: PWGSC File #W7702-155729 2.1.1 The Contractor/Offeror must, at all times during the performance of the Contract/Standing Offer, hold a valid Designated Organization Screening (DOS), issued by the Canadian Industrial Security Directorate (CISD), Public Works and Government Services Canada (PWGSC). 2.1.2 The Contractor/Offeror personnel requiring access to sensitive work site(s) must EACH hold a valid RELIABILITY STATUS, granted or approved by CISD/PWGSC. 2.1.3 Subcontracts which contain security requirements are NOT to be awarded without the prior written permission of CISD/PWGSC. 2.1.4 The Contractor/Offeror must comply with the provisions of the: (a) Security Requirements Check List and security guide (if applicable), attached at Annex "C" of the Solicitation; (b) Industrial Security Manual (Latest Edition). 3. REQUIREMENT: Defence Research and Development Canada - Suffield Research Station has a project to support the ongoing efforts to provide the Canadian Armed Forces with medical countermeasures to protect them against hazards while on operations. Adult stem cells are therapeutic tools with promise in accelerating healing and tissue regeneration, and as engineered cells that produce therapeutic molecules. Mesenchymal stem cells are non-embryonic adult cells sourced in this case from umbilical cord tissue (usually treated as waste) following normal births. This contract will NOT involve tissue or cell collection; cells will be obtained from commercial suppliers. Our aim is to develop mesenchymal stem cells (MSC) to address capability gaps in medical countermeasures (MCMs) available to the Canadian Armed Forces. In clinical trials, human MSC have consistently proven safe for transplant, and regulatory approval for MSC-derived therapeutic products has already been established. This effort will extend our understanding of the utility of mesenchymal stem cells as therapeutic tools, using a combination of native cells, recombinant protein expression constructs in MSC, and cell or media extracts. Some basic properties of MSC will be characterized, such as in vivo survival, in vitro stability on expansion in culture, genetic stability in extended culture, and differentiation versus culture condition or time. To qualify a bid will have to consist of no less than 80% of goods and/or services of Canadian origin. WARNING: FACSIMILE BIDS WILL NOT BE ACCEPTED due to the nature of this solicitation. 4. EVALUATION AND SELECTION: Evaluation: Mandatory and point rated technical and management evaluation criteria are included in Annex "F" of the solicitation. Contractor selection: The responsive bid with the highest number of points will be recommended for award of a contract, provided that the total evaluated price does not exceed the budget available for this requirement. 5. OWNERSHIP OF INTELLECTUAL PROPERTY: Any intellectual property arising from the performance of the Work under the Contract will vest in the Contractor. 6. CANADA'S MAXIMUM FUNDING AND ADDITIONAL CONTRACTOR FUNDING Canada's maximum funding available for the contract resulting from the bid solicitation is $490,000.00 [Contract Term: $360,000.00; Option Period: $130,000.00] (Applicable Taxes extra, as appropriate). Any cost in excess of the maximum funding will be construed as a Contractor's commitment of additional funding to the Contract. This disclosure does not commit Canada to pay the maximum funding available. 7. PERIOD OF CONTRACT: It is anticipated that any contract will be effective from date of Contract to 2017-03-31 inclusive, with the irrevocable option to extend the term of the Contract by up to one (1) additional one (1) year periods (Period 1: 2017-04-01 to 2018-03-31). Contracting Authority Lorraine Jenkinson Supply Specialist Public Works and Government Services Canada Acquisitions Branch, Western Region ATB Place ATB, North Tower 10025 Jasper Avenue, 5e étage Edmonton, AB T5J 1S6 Telephone: (780) 497-3593 Facsimile: (780) 497-3510 E-mail address: Lorraine.Jenkinson@pwgsc-tpsgc.gc.ca Delivery Date: Above-mentioned The Crown retains the right to negotiate with suppliers on any procurement. Documents may be submitted in either official language of Canada.
Contract duration
Refer to the description above for full details.
Trade agreements
-
Agreement on Internal Trade (AIT)
Contact information
Contracting organization
- Organization
-
Public Works and Government Services Canada
- Address
-
11 Laurier St, Phase III, Place du PortageGatineau, Quebec, K1A 0S5Canada
- Contracting authority
- Jenkinson, Lorraine
- Phone
- (780) 497-3593 ( )
- Fax
- (780) 497-3510
- Address
-
ATB Place North Tower
10025 Jasper Ave./10025 ave Jasper
5th floor/5e étageEdmonton, Alberta, T5J 1S6
Buying organization(s)
- Organization
-
Department of National Defence
- Address
-
101 Colonel By DrOttawa, Ontario, K1A0K2Canada
Bidding details
Full details regarding this tender opportunity are available in the documents below. Click on the document name to download the file. Contact the contracting officer if you have any questions regarding these documents.
Document title | Amendment no. | Language | Unique downloads | Date added |
---|---|---|---|---|
ABES.PROD.PW_EDM.B607.F10430.EBSU001.PDF | 001 |
French
|
3 | |
ABES.PROD.PW_EDM.B607.E10430.EBSU001.PDF | 001 |
English
|
4 | |
ABES.PROD.PW_EDM.B607.F10430.EBSU000.PDF | 000 |
French
|
4 | |
ABES.PROD.PW_EDM.B607.E10430.EBSU000.PDF | 000 |
English
|
29 |
Access the Getting started page for details on how to bid, and more.